We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Which product type to select when submitting a notification of intent to market e-cigarette and vape products in Great Britain.
The types of emissions a manufacturer or importer of e-cigarettes should notify us about.
Types of ingredients permitted in nicotine-containing liquids in electronic cigarettes and refill containers.
Submitting annual reports on sales of electronic cigarettes and refill containers.
UK government interpretation of the requirements for labelling e-liquids for Northern Ireland.
Due diligence for suppliers of e-cigarettes and e-liquids.
Guidance and specifications for the recording and extraction of CTAD data from laboratories in England processing LA and NHS commissioned chlamydia tests.
Information relating to the disapplication of falsified medicines under UK Law.
Guidance for dispensing of valproate-containing medicines in the manufacturer’s original full pack, following amendments to the Human Medicines Regulations (HMRs).
Information and advice on submitting a dermatological product to the Advisory Committee for Borderline Substances (ACBS).
Information on how the ACBS factors in the issue of pricing, when reviewing product applications.
Information for local authorities in England about the grant, which will support local authorities to deliver routine commissioning of PrEP in 2020 to 2021.
How to use RamaXL, including system availability, running reports and how to subscribe.
Helping interpret the Human Medicines (Amendment) Modular Manufacture and Point of Care regulations 2025.
Deficiencies in Omega’s pharmacovigilance system are not thought to affect the safety of the products that they market.
A summary of actions related to problems with T34 syringe drivers
Information about the types of content published by the MHRA.
Advice for manufacturers, members of the public and professional users of software or apps being used during the COVID-19 pandemic.
Information for pharmaceutical wholesalers explaining the main changes the Windsor Framework introduces to the packaging for all medicines licensed in the UK, effective from 1 January 2025.
Supplementary information for international regulators on packaging changes and the export of UK medicines.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).